RecruitingNCT06905145
Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis
Sponsor
National Cancer Institute, Naples
Enrollment
128 participants
Start Date
May 3, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational, prospective study enrolling patients who meet the inclusion criteria and provide consent for the use of biopsy samples collected as part of standard clinical practice. The analysis will focus on the following biomarkers: TP53, P16, Cyclin D1, EGFR, Akt, PDL-1, and ERCC1. These biomarkers will be examined in both observation groups.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Patients aged \> 18 years
- Written informed consent approved by the competent Independent Ethics Committee
- Histopathological diagnosis of squamous cell carcinoma of the head and neck region originating from one of the following organs or structures: Oral cavity, oropharynx, larynx, hypopharynx
- Locally advanced stage: from T1N1M0 to T4N3M0
- Availability of a tissue sample from a biopsy performed according to clinical practice guidelines.
Exclusion Criteria2
- Recurrent/metastatic disease
- Presence of a synchronous second tumor
Interventions
OTHERBiomarkers evaluation
Evaluate the prognostic role of the markers TP53, P16, Cyclin D1, EGFR, Akt, PDL-1, ERCC1 examined on biopsy samples.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06905145
Related Trials
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT069800383 locations
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT0563564316 locations
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
NCT043753841 location
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT0680685257 locations
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT0711504311 locations